We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
What's that got to do with it? Are you an Accustem denyer?
I wouldn't make any assumption about goods news based on the green box count. Still, each to his own.
I have loads of green boxes today. Must be good news soon then
Sorry I managed to read it before it through me out.
Interesting bit about Tils requiring the Milan institute to carry on with project as a part of the licence.
Interesting read.
https://www.lawinsider.com/contracts/6Y7ovTG1Z0K
Unfortunately, I believe, as Accustem is a private limited company it does not have to inform shareholders what they are doing except at an AGM, if this is so, they could be doing nothing or advancing very quickly, more money could have been raised privately and as stated Tils agreed to invest about £2 million was it , on completion of demerger. They are not obliged to tell us. Except Tils should tell us extra £2 million has been put in Accustem.
Denny11, I believe that should have happened in H1 2021, however, they separated Accustem with £1m, so I don't believe they would have had the funds to do what was proposed. No information from TILS or via Accustem website. GC stated he had not recruited a Team to run Accustem around Mar/Apr 21. Hence my thoughts of 15 months with no progress.
BB
Thanks LBC, I read the SEC filing but couldn't see how the £1.50 issue price was confirmed anywhere. I believe they have the ADR's to issue at any price up to a value of $250m. Lets hope they will wait until TLSA is a hot stock and raise at a good price - Foralumab POC.
BB
My memory tells me that there was something said that they were transferring StemPrintER development out to Italy (was it to a university?) but I don't recall them saying that it would be stalled.
Either way, Accustem valued @ 15p or 30p. The process to separate was due to no value being given to Accustem according to GC in a video chat.
The RNS dated, 22 May 20 stated ( Tils Closed @96p on that day - 27p higher than today):
'The rationale of this decision is that, as a standalone genomics-based personalized medicine company and separate legal entity, StemPrintER could:
· Secure separate financial resources, with the goal of enabling accelerated development of the StemPrintER genomic test:
· Separate StemPrintER from Tiziana's biotechnology and pharmaceutical businesses so it may focus on the personalized medicine market; and
· Allow Shareholders to benefit from both Tiziana's rapidly developing drug portfolio and the standalone value of StemPrintER as it progresses through its own development milestones and the path to commercialization and allow shareholders to receive the maximum potential value from StemPrintER as a standalone entity.'
Unfortunately, StemprintER has not progressed in the last 15 months, as far as we are aware.
However, TILS has progressed with various treatments and we are 27p lower than when the announcement was made. I'm still a believer of TILS, but Accustem is in danger of being over taken by advances in other diagnostic methods (blood testing etc) or even advances in treatments for Cancer.
BB
Hi Bluebelly, I think this is the document your referring to https://ir.tizianalifesciences.com/node/9201/html
We may offer, issue and sell from time to time up to $250,000,000, or its equivalent in any other currency, currency units, or composite currency or currencies, of our ordinary shares, in the form of American Depositary Shares, or ADSs, warrants to purchase ordinary shares, in the form of ADSs and a combination of such securities, separately or as units, in one or more offerings. Each ADS represents 2 ordinary shares. This prospectus provides a general description of offerings of these securities that we may undertake.
We refer to our ADSs, ordinary shares, warrants, and units collectively as “securities” in this prospectus.
Each time we sell our securities pursuant to this prospectus, we will provide the specific terms of such offering in a supplement to this prospectus. The prospectus supplement may also add, update, or change information contained in this prospectus. You should read this prospectus, the accompanying prospectus supplement, together with the additional information described under the heading “Where You Can Find More Information,” before you make your investment decision.
We may, from time to time, offer to sell the securities, through public or private transactions, directly or through underwriters, agents or dealers, on or off The Nasdaq Global Market, at prevailing market prices or at privately negotiated prices. If any underwriters, agents or dealers are involved in the sale of any of these securities, the applicable prospectus supplement will set forth the names of the underwriter, agent or dealer and any applicable fees, commissions or discounts.
Our ADSs issued in connection with our November 2018 initial public offering in the United States are listed on The Nasdaq Global Market under the symbol “TLSA”. On January 25, 2021, the last reported price of our ADSs on The Nasdaq Global Market was $3.71 per ADS.
Our ordinary shares are admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority, or the FCA, and to trading on the main market for listed securities, or Main Market, of London Stock Exchange plc, or the London Stock Exchange, under the symbol “TILS.” On January 25, 2021, the last reported price of our ordinary shares was £1.50 per share (equivalent to $4.11 per ADS based on an exchange rate of £1.00 to $1.3685).
We are an “emerging growth company,” as defined by the Jumpstart Our Business Startups Act of 2012, or JOBS Act, and as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings.
Investing in our securities involves a high degree of risk. Please carefully consider the risks discussed in this prospectus under “Risk Factors” in this prospectus, in any accompanying prospectus supplement and in the documents incorporated by reference i
You can buy Accustem ADR’s by calling HL. Phone orders only. They have stock
Currently un tradeable here so actually feels like worth sweet f.a. Really hope we hear something soon in which direction it is going to go.
From https://www.investopedia.com/ask/answers/06/adrvsads.asp
An American depositary receipt (ADR) allows foreign companies to list their shares on U.S. stock exchanges.
An American depositary share (ADS) is the U.S. dollar-denominated equity share of a foreign-based company available for purchase on an American stock exchange.
The entire issuance is called an American Depositary Receipt (ADR), and the individual shares are referred to as ADS.
I think the nub is whether the quoted price we are seeing is for one actual share or one ADx, whatever two shares is called, which is two shares.
If you look up TLSA share price it is showing the ADR price not the individual share price, as we know a TILS share is not worth the value shown. https://www.cnbc.com/quotes/tlsa?qsearchterm=tlsa
So it doesn't seem unreasonable to assume that if you look up Accustem on the same platform it will also be showing the ADR price. https://www.cnbc.com/quotes/ACMSY - i.e. a share is worth half that value (currently $0.44 so $0.22 approx 15.7p)
ADS not ADR
No it’s 2 two Accustem ords for one Accustem ADR (OTC ticker ACMSY). Same as relationship as between TILS ords and TLSA ADRs.
Interesting warning !!
https://www.otcmarkets.com/stock/ACMSY/overview
Well all I can think of is because it’s in US and as the only tradable shares are ADR what else can it be but as the SEC registered shares. US shareholders received ADRs ??.
https://www.investopedia.com/terms/p/pinksheets.asp
Still no clearer, but its not an official listing. So are ADR's required, as they would be for an official listing.
BB
Well on the other website I posted a link to says they are ADR. (ADFVN the dark side , I would not go there, a couple of good posters but just full of trolls. Pity)
Cloudy. Correct. Any unsure posters should read the RNS of 8th July. Ix ADS equals 2 x Accustem shares. No need for any doubt.
Are the OTC PK's trading ADR's or ordinary shares of Accustem Sciences Limited?
As Accustem are not yet listed are ADR's available?
Any holders of ADR's care to comment or explain what they have been given for their holding.
BB
Couldn’t be clearer, SEC says 2 shares for 1 ADR. I’m no expert but that is what it says.
Hi SK
I think there is still confusion here wrt Accustem shares. The SEC filing stated:
American Depositary Shares evidenced by American Depositary Receipts, each American Depositary Share representing two ordinary shares of Accustem Sciences Limited.
See Document link:
https://www.sec.gov/Archives/edgar/data/0001850767/000138713121006805/accu-f6_062221.htm
Everything has been unclear with the Accustem listing.
BB
Hi All
I think ther is some confusion on here ref the Accustem ADR share price ! American Tiziana ADR hold two Tiziana shares whereas the new Accustem ADR Shares ar a single share as far as I understand so the current value of Accustem Share is
$0.42 up+0.02 (+5.00%)
https://www.cnbc.com/quotes/ACMSY
Which at the current exchang rate is 30p
Good Luck All
StarKnight
My hp account still shows accustem shares as 0 value?